Black Diamond Therapeutics Shares Jump on Positive Silevertinib Phase 2 Data and Strong Cash Runway

Black Diamond Therapeutics reported Q2 results with robust silevertinib responses, no new brain mets, and cash expected to last into the second half of 2028.